|
JP6352950B2
(ja)
*
|
2013-03-08 |
2018-07-04 |
ノバルティス アーゲー |
活性薬物の送達のための脂質と脂質組成物
|
|
CN105683163B
(zh)
|
2013-10-04 |
2018-11-09 |
诺华股份有限公司 |
RNA干扰中使用的RNAi剂的3’端帽
|
|
WO2015051366A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Novel formats for organic compounds for use in rna interference
|
|
JP6546161B2
(ja)
|
2013-10-04 |
2019-07-17 |
ノバルティス アーゲー |
Ｂ型肝炎ウイルスを治療するための有機化合物
|
|
EP3082760A1
(en)
*
|
2013-12-19 |
2016-10-26 |
Novartis AG |
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
|
|
HUE057800T2
(hu)
|
2014-04-23 |
2022-06-28 |
Modernatx Inc |
Nukleinsav vakcinák
|
|
EP4223285A3
(en)
*
|
2014-07-16 |
2023-11-22 |
Novartis AG |
Method of encapsulating a nucleic acid in a lipid nanoparticle host
|
|
WO2016054237A2
(en)
*
|
2014-10-03 |
2016-04-07 |
Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center |
Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
|
|
US10792299B2
(en)
|
2014-12-26 |
2020-10-06 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
US20180002702A1
(en)
|
2014-12-26 |
2018-01-04 |
Nitto Denko Corporation |
Methods and compositions for treating malignant tumors associated with kras mutation
|
|
US10264976B2
(en)
*
|
2014-12-26 |
2019-04-23 |
The University Of Akron |
Biocompatible flavonoid compounds for organelle and cell imaging
|
|
US11007260B2
(en)
|
2015-07-21 |
2021-05-18 |
Modernatx, Inc. |
Infectious disease vaccines
|
|
US12150980B2
(en)
|
2015-07-30 |
2024-11-26 |
Modernatx, Inc. |
Concatemeric peptide epitope RNAs
|
|
KR102630720B1
(ko)
*
|
2015-08-28 |
2024-01-29 |
세키스이 메디칼 가부시키가이샤 |
벤질 화합물
|
|
GB201518172D0
(en)
*
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
|
ES2922760T3
(es)
|
2015-10-22 |
2022-09-20 |
Modernatx Inc |
Vacunas de virus respiratorios
|
|
TN2018000152A1
(en)
*
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
MY192848A
(en)
|
2015-12-28 |
2022-09-12 |
Intellia Therapeutics Inc |
Compositions and methods for the treatment of hemoglobinopathies
|
|
US20190136231A1
(en)
|
2016-03-30 |
2019-05-09 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle formulations for crispr/cas components
|
|
CA3021647A1
(en)
|
2016-04-22 |
2017-10-26 |
Intellia Therapeutics, Inc. |
Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
|
|
JP7246930B2
(ja)
|
2016-05-18 |
2023-03-28 |
モデルナティエックス インコーポレイテッド |
インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
|
|
CA3024509A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
JP2019528312A
(ja)
|
2016-08-07 |
2019-10-10 |
ノバルティス アーゲー |
ｍＲＮＡ媒介性の免疫化方法
|
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
EP3532103B1
(en)
*
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
EP4043031A3
(en)
|
2016-11-17 |
2022-11-23 |
GlaxoSmithKline Biologicals SA |
Zika viral antigen constructs
|
|
JP2019535795A
(ja)
*
|
2016-11-28 |
2019-12-12 |
セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ |
口腔感染症の処置のための組成物及び方法
|
|
AU2017379073B2
(en)
*
|
2016-12-22 |
2023-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
BR112019013192A2
(pt)
*
|
2016-12-26 |
2019-12-10 |
Cellix Bio Private Ltd |
composto e composição farmacêutica
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
KR20250093420A
(ko)
|
2017-09-29 |
2025-06-24 |
인텔리아 테라퓨틱스, 인크. |
게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
|
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
AU2018338967B2
(en)
|
2017-09-29 |
2025-04-24 |
Intellia Therapeutics, Inc. |
In vitro method of mRNA delivery using lipid nanoparticles
|
|
HUE066630T2
(hu)
|
2017-09-29 |
2024-08-28 |
Intellia Therapeutics Inc |
Készítmények
|
|
MA54676A
(fr)
|
2018-01-29 |
2021-11-17 |
Modernatx Inc |
Vaccins à base d'arn contre le vrs
|
|
CA3109165A1
(en)
|
2018-08-17 |
2020-02-20 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
KR20210093871A
(ko)
*
|
2018-10-02 |
2021-07-28 |
인텔리아 테라퓨틱스, 인크. |
이온화 가능한 아민 지질
|
|
WO2020081613A1
(en)
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
MX2021004276A
(es)
|
2018-10-18 |
2021-09-08 |
Intellia Therapeutics Inc |
Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina.
|
|
US20200268906A1
(en)
|
2018-10-18 |
2020-08-27 |
Intellia Therapeutics, Inc. |
Nucleic acid constructs and methods of use
|
|
TWI860300B
(zh)
|
2018-10-18 |
2024-11-01 |
美商英特利亞醫療公司 |
用於從白蛋白基因座表現轉殖基因的組成物及方法
|
|
US12214023B2
(en)
|
2018-10-18 |
2025-02-04 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor IX
|
|
BR112021010853A2
(pt)
|
2018-12-05 |
2021-08-31 |
Intellia Therapeutics, Inc. |
Lipídios de amina modificados
|
|
WO2020190750A1
(en)
|
2019-03-15 |
2020-09-24 |
Modernatx, Inc. |
Hiv rna vaccines
|
|
JP7636338B2
(ja)
|
2019-03-28 |
2025-02-26 |
インテリア セラピューティクス，インコーポレイテッド |
コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用
|
|
AU2020248470A1
(en)
|
2019-03-28 |
2021-11-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for polypeptide expression
|
|
PH12021552301A1
(en)
|
2019-03-28 |
2022-07-04 |
Intellia Therapeutics Inc |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
MX2021012934A
(es)
|
2019-04-25 |
2022-04-06 |
Intellia Therapeutics Inc |
Lipidos de amina ionizables y nanoparticulas lipidicas.
|
|
US20220259617A1
(en)
|
2019-06-13 |
2022-08-18 |
The General Hospital Corporation |
Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
|
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
|
MX2022000879A
(es)
|
2019-07-21 |
2022-05-02 |
Glaxosmithkline Biologicals Sa |
Vacuna viral terapeutica.
|
|
EP4021415B1
(en)
|
2019-09-01 |
2025-05-14 |
Nextage Therapeutics Ltd. |
Cannabinoid containing targeting liposomes
|
|
AU2020397956A1
(en)
|
2019-12-04 |
2022-07-07 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
|
US20230279394A1
(en)
|
2019-12-18 |
2023-09-07 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
WO2021141969A1
(en)
|
2020-01-09 |
2021-07-15 |
Guide Therapeutics, Inc. |
Nanomaterials
|
|
KR20230057487A
(ko)
|
2020-03-04 |
2023-04-28 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
게놈 조정을 위한 방법 및 조성물
|
|
EP4135761A1
(en)
|
2020-04-16 |
2023-02-22 |
GlaxoSmithKline Biologicals S.A. |
Sars cov-2 spike protein construct
|
|
JP2023524666A
(ja)
|
2020-04-28 |
2023-06-13 |
インテリア セラピューティクス，インコーポレイテッド |
インビトロ細胞送達の方法
|
|
WO2021236930A1
(en)
|
2020-05-20 |
2021-11-25 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
EP4153224A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus antigen compositions and their uses
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
US20230234992A1
(en)
|
2020-06-05 |
2023-07-27 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
US20230256090A1
(en)
|
2020-06-29 |
2023-08-17 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
CN116670154A
(zh)
|
2020-07-24 |
2023-08-29 |
总医院公司 |
增强的病毒样颗粒及使用其递送至细胞的方法
|
|
WO2022051629A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
CA3189073A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Lipid conjugates for the delivery of therapeutic agents
|
|
EP4213882A4
(en)
|
2020-09-15 |
2025-02-26 |
Verve Therapeutics, Inc. |
LIPID FORMULATIONS FOR GENE EDITING
|
|
CZ2020529A3
(cs)
*
|
2020-09-23 |
2022-03-30 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
US11591544B2
(en)
|
2020-11-25 |
2023-02-28 |
Akagera Medicines, Inc. |
Ionizable cationic lipids
|
|
CN113185421B
(zh)
*
|
2020-11-27 |
2022-01-25 |
广州市锐博生物科技有限公司 |
脂质化合物及其组合物
|
|
IL303506A
(en)
|
2020-12-11 |
2023-08-01 |
Intellia Therapeutics Inc |
Polynucleotides, compositions, and methods for genome editing involving deamination
|
|
MX2023007630A
(es)
|
2020-12-23 |
2023-08-25 |
Flagship Pioneering Innovations Vi Llc |
Composiciones de trem modificadas y usos de las mismas.
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
IL304069A
(en)
|
2020-12-30 |
2023-08-01 |
Intellia Therapeutics Inc |
Engineered T cells
|
|
IL303845A
(en)
|
2021-01-20 |
2023-08-01 |
Beam Therapeutics Inc |
Nanomaterials include a degradable property
|
|
JP2024502954A
(ja)
*
|
2021-01-20 |
2024-01-24 |
ビーム セラピューティクス インク． |
ナノ材料
|
|
CN116963729A
(zh)
*
|
2021-01-20 |
2023-10-27 |
比姆医疗股份有限公司 |
包括可电离脂质的纳米材料
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
CN118026871A
(zh)
*
|
2021-02-05 |
2024-05-14 |
嘉晨西海(杭州)生物技术有限公司 |
一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用
|
|
CN112961065B
(zh)
*
|
2021-02-05 |
2023-03-14 |
嘉晨西海(杭州)生物技术有限公司 |
一种可电离脂质分子及其制备方法及其在制备脂质纳米颗粒的应用
|
|
US20240181037A1
(en)
|
2021-03-26 |
2024-06-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
KR20230165276A
(ko)
|
2021-03-31 |
2023-12-05 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
|
|
JP7796311B2
(ja)
|
2021-04-09 |
2026-01-09 |
相互薬工株式会社 |
脂質および組成物
|
|
TW202308597A
(zh)
|
2021-04-17 |
2023-03-01 |
美商英特利亞醫療公司 |
脂質奈米顆粒組合物
|
|
CR20230535A
(es)
|
2021-04-17 |
2024-02-16 |
Intellia Therapeutics Inc |
Inhibidores de proteína cinasa dependiente de adn y composiciones y usos de estos
|
|
KR20240017793A
(ko)
|
2021-04-17 |
2024-02-08 |
인텔리아 테라퓨틱스, 인크. |
지질 나노입자 조성물
|
|
WO2022248353A1
(en)
|
2021-05-24 |
2022-12-01 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
EP4352247A1
(en)
|
2021-06-09 |
2024-04-17 |
GlaxoSmithKline Biologicals s.a. |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
KR20240032013A
(ko)
|
2021-06-10 |
2024-03-08 |
인텔리아 테라퓨틱스, 인크. |
유전자 편집을 위한 내부 링커를 포함하는 변형된 가이드 rna
|
|
US20250127809A1
(en)
|
2021-06-23 |
2025-04-24 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
|
EP4387597A1
(en)
|
2021-08-16 |
2024-06-26 |
GlaxoSmithKline Biologicals SA |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
US20250134824A1
(en)
|
2021-08-16 |
2025-05-01 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
JP2024534915A
(ja)
|
2021-09-03 |
2024-09-26 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
自己増幅性メッセンジャーリボ核酸におけるヌクレオチド塩基の置換
|
|
AU2022343268A1
(en)
|
2021-09-08 |
2024-03-28 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating a genome
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
MX2024004618A
(es)
|
2021-10-18 |
2024-07-12 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para purificar polirribonucleotidos.
|
|
US20240415980A1
(en)
|
2021-10-28 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
WO2023081689A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
CN118541346A
(zh)
|
2021-11-08 |
2024-08-23 |
奥纳治疗公司 |
用于递送环状多核苷酸的脂质纳米颗粒组合物
|
|
EP4436983A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Varicella-zoster virus immunogen compositions and their uses
|
|
CN118900845A
(zh)
|
2021-11-24 |
2024-11-05 |
旗舰创业创新六公司 |
冠状病毒免疫原组合物及其用途
|
|
JP2024541465A
(ja)
|
2021-11-24 |
2024-11-08 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
免疫原性組成物及びその使用
|
|
WO2023102364A1
(en)
*
|
2021-12-02 |
2023-06-08 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Antiviral compounds, compositions and uses thereof
|
|
CA3239381A1
(en)
|
2021-12-03 |
2023-06-08 |
David R. Liu |
Compositions and methods for efficient in vivo delivery
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
AU2022420620A1
(en)
|
2021-12-23 |
2024-07-04 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
US20250134825A1
(en)
*
|
2022-02-02 |
2025-05-01 |
Mslsolutions Gmbh |
Method for producing medications and vaccines
|
|
CA3242731A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
JP2023130120A
(ja)
*
|
2022-03-07 |
2023-09-20 |
スペラファーマ株式会社 |
ペプチド合成方法
|
|
WO2023178065A2
(en)
*
|
2022-03-15 |
2023-09-21 |
Broadpharm Inc. |
Lipid compounds and lipid nanoparticles
|
|
CN119072464A
(zh)
*
|
2022-03-25 |
2024-12-03 |
赛欧生物医药股份有限公司 |
新型可电离脂质和脂质纳米颗粒以及其使用方法
|
|
EP4504252A2
(en)
|
2022-04-08 |
2025-02-12 |
Flagship Pioneering Innovations VII, LLC |
Vaccines and related methods
|
|
US20250302998A1
(en)
|
2022-05-09 |
2025-10-02 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
|
US20250295687A1
(en)
|
2022-05-09 |
2025-09-25 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
|
CN120303407A
(zh)
|
2022-05-17 |
2025-07-11 |
恩维洛普治疗有限责任公司 |
用于有效体内递送的组合物和方法
|
|
AU2023295529A1
(en)
|
2022-06-16 |
2024-12-12 |
Intellia Therapeutics, Inc. |
Methods and compositions for genetically modifying a cell
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4544043A1
(en)
|
2022-06-22 |
2025-04-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions of modified trems and uses thereof
|
|
CN119585419A
(zh)
|
2022-06-29 |
2025-03-07 |
因特利亚治疗公司 |
工程化t细胞
|
|
CN117486738B
(zh)
*
|
2022-07-15 |
2025-08-12 |
中国科学院基础医学与肿瘤研究所(筹) |
一种脂质分子及其组合物
|
|
AU2023311822A1
(en)
|
2022-07-20 |
2025-01-09 |
Beam Therapeutics Inc. |
Nanomaterials comprising triols
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
IL318711A
(en)
|
2022-08-01 |
2025-03-01 |
Flagship Pioneering Innovations Vii Llc |
Immune modulator proteins and related methods
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
AU2023372397A1
(en)
|
2022-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
EP4615517A1
(en)
|
2022-11-08 |
2025-09-17 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
AU2023379457A1
(en)
|
2022-11-14 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024129988A1
(en)
|
2022-12-14 |
2024-06-20 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for delivery of therapeutic agents to bone
|
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
EP4637812A1
(en)
|
2022-12-19 |
2025-10-29 |
GlaxoSmithKline Biologicals S.A. |
Hepatitis b compositions
|
|
EP4638783A2
(en)
|
2022-12-22 |
2025-10-29 |
Intellia Therapeutics, Inc. |
Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies
|
|
CN120418427A
(zh)
|
2022-12-23 |
2025-08-01 |
因特利亚治疗公司 |
用于基因组编辑的系统和方法
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
疫苗及相關方法
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151685A1
(en)
|
2023-01-09 |
2024-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
KR20250151427A
(ko)
|
2023-02-13 |
2025-10-21 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
치료적 조성물을 위한 절단성 링커 함유 이온화 가능한 지질 및 지질 담체
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
TW202446956A
(zh)
|
2023-02-17 |
2024-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
包含經修飾的胞嘧啶的ｄｎａ組成物
|
|
US20240285805A1
(en)
|
2023-02-17 |
2024-08-29 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified uracil
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024216191A1
(en)
|
2023-04-12 |
2024-10-17 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
KR20250171373A
(ko)
|
2023-04-12 |
2025-12-08 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
미스센스 돌연변이 교정용 trem
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
AU2024260120A1
(en)
|
2023-04-27 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
AU2024275548A1
(en)
|
2023-05-19 |
2026-01-08 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
CN116535381B
(zh)
*
|
2023-07-06 |
2023-10-17 |
北京悦康科创医药科技股份有限公司 |
具有五元环缩醛结构的阳离子脂质化合物、包含其的组合物及用途
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
Ｃａｓ內切酶及相關方法
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
US20250268826A1
(en)
|
2023-09-18 |
2025-08-28 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
US20250162981A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
TW202523695A
(zh)
|
2023-11-22 |
2025-06-16 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於治療非酒精性脂肪性肝病之方法及組成物
|
|
WO2025117732A1
(en)
*
|
2023-11-29 |
2025-06-05 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025137301A1
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Methods for rapid engineering of cells
|
|
WO2025137439A2
(en)
|
2023-12-20 |
2025-06-26 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025265017A1
(en)
|
2024-06-20 |
2025-12-26 |
Regeneron Pharmaceuticals, Inc. |
Ass1 gene insertion for the treatment of citrullinemia type i
|
|
WO2026006577A1
(en)
|
2024-06-26 |
2026-01-02 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
CN119462481B
(zh)
*
|
2025-01-17 |
2025-04-25 |
北京悦康科创医药科技股份有限公司 |
Sting激活型佐剂脂质、包含其的组合物及用途
|